Palisade Bio (PALI) Other Accumulated Expenses (2012 - 2026)
Palisade Bio (PALI) reported Other Accumulated Expenses of $219000.0 for Q1 2026, down 49.42% on a QoQ basis from $433000.0 in Q4 2025.
Palisade Bio (PALI) has 15 years of Other Accumulated Expenses data on file, last reported at $219000.0 in Q1 2026.
- Quarterly Other Accumulated Expenses changed N/A year-over-year to $219000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $219000.0 (changed N/A YoY) and the FY2025 annual result came in at $433000.0, up 448.1% from the prior year.
- Other Accumulated Expenses retreated to $219000.0 in Q1 2026 per PALI's latest filing, from $433000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $433000.0 in Q4 2025 and bottomed at $11000.0 in Q2 2022.
- The 5-year median for Other Accumulated Expenses is $180000.0 (2023), against an average of $156857.1.
- The widest annual swing landed in 2022, when Other Accumulated Expenses slumped 86.25%; it then jumped 775.0% in 2024.
- Tracing PALI's Other Accumulated Expenses over 5 years: stood at $88000.0 in 2022, then jumped by 106.82% to $182000.0 in 2023, then tumbled by 56.59% to $79000.0 in 2024, then jumped by 448.1% to $433000.0 in 2025, then tumbled by 49.42% to $219000.0 in 2026.
- Per Business Quant, the three latest PALI Other Accumulated Expenses figures stand at $219000.0 (Q1 2026), $433000.0 (Q4 2025), and $202000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 219,000.00 |
| Dec 31, 2025 | 433,000.00 |
| Sep 30, 2025 | 202,000.00 |
| Jun 30, 2025 | 260,000.00 |
| Dec 31, 2024 | 79,000.00 |
| Sep 30, 2024 | 235,000.00 |
| Jun 30, 2024 | 210,000.00 |
| Mar 31, 2024 | 178,000.00 |
| Dec 31, 2023 | 182,000.00 |
| Sep 30, 2023 | 46,000.00 |
| Jun 30, 2023 | 24,000.00 |
| Mar 31, 2023 | 29,000.00 |
| Dec 31, 2022 | 88,000.00 |
| Jun 30, 2022 | 11,000.00 |
| Sep 30, 2021 | 27,000.00 |
| Jun 30, 2021 | 80,000.00 |
| Dec 31, 2020 | 88,000.00 |
| Jun 30, 2019 | 19,537.00 |
| Mar 31, 2019 | 126,930.00 |
| Dec 31, 2018 | 218,602.00 |
| Sep 30, 2018 | 348,928.00 |
| Jun 30, 2018 | 52,933.00 |
| Mar 31, 2018 | 109,266.00 |
| Dec 31, 2017 | 220,879.00 |
| Sep 30, 2017 | 358,044.00 |
| Jun 30, 2017 | 67,992.00 |
| Mar 31, 2017 | 349,087.00 |
| Dec 31, 2016 | 430,738.00 |
| Sep 30, 2016 | 538,350.00 |
| Jun 30, 2016 | 204,464.00 |
| Mar 31, 2016 | 241,008.00 |
| Dec 31, 2015 | 263,104.00 |
| Sep 30, 2015 | 207,292.00 |
| Jun 30, 2015 | 148,536.00 |
| Mar 31, 2015 | 52,856.00 |
| Dec 31, 2014 | 126,745.00 |
| Sep 30, 2014 | 202,383.00 |
| Jun 30, 2014 | 13,139.00 |
| Mar 31, 2014 | 53,280.00 |
| Dec 31, 2013 | 93,426.00 |
| Sep 30, 2013 | 174,345.00 |
| Jun 30, 2013 | 10,633.00 |
| Mar 31, 2013 | 42,566.00 |
| Dec 31, 2012 | 90,776.00 |
| Sep 30, 2012 | 138,987.00 |